[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhengzhou University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":179},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,64,85,111,133,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100615955","zanubrutinib-rituximab-and-lenalidomide-in-the-first-line-treatment-of-marginal-zone-lymphoma-100615955",false,"NCT07299331","Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma","A Multicenter, Single-Arm, Prospective Clinical Study of Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma","Inclusion Criteria:\n\n1. 18-75 years\n2. Histologically confirmed MZL in untreated stage III or IV and needed for therapy as determined by the treating physician\n3. ECOG performance status 0-2\n4. Expected survival ≥ 6 months\n5. Adequate hematologic and organ function: absolute neutrophil count ≥1,000\u002Fmm3 (independent of growth factor support), platelet counts ≥75,000\u002Fmm3, serum aspartate transaminase or alanine transaminase less than 2.5 times the upper limit of normal (ULN), serum creatinine ≤1.5×ULN, and bilirubin ≤1.5×ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of nonhepatic origin, in which case bilirubin should not exceed 3 g\u002FdL, left ventricular ejection fraction (LVEF) of the heart≥ 50%\n6. Women of childbearing potential and men who were sexually active were required to be practicing a highly effective method of birth control during and after the study\n7. No history of other malignant tumors\n8. At least one measurable lesion with a longest diameter of ≥ 1.5 cm or measurable lesions of extranodal lesions ≥ 1.0 cm.\n9. Able to understand the study and provide signed Informed Consent Form\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Active central nervous system lymphoma\n3. Previous anti-tumor treatment\n4. A severe immediate-type hypersensitivity reaction history for any of the drugs used in this study\n5. History of stroke or intracranial hemorrhage within 6 months before study entry\n6. Received a live attenuated vaccine within 4 weeks prior to enrollment History of human immunodeficiency virus, or active hepatitis C virus, or active hepatitis B virus infection, or any uncontrolled active systemic infection\n7. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification\n8. Other serious medical conditions that might have an impact on this study","ALL","18 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment. The main questions it aims to answer are Does the combined therapy prolong patient survival? What medical problems do participants have when using this therapeutic approach? Researchers will observe the treatment to see if it works well than conventional therapies.\n\nParticipants will Administer drugs as required by the protocol Visit the clinic regularly for checkups and tests Keep a diary of their symptoms, examination and laboratory test indicators",[27],"Marginal Zone Lymphoma(MZL)","NOT_YET_RECRUITING","2025-12-22",{"date":31,"type":32},"2025-12-23","ACTUAL",{"date":34,"type":21},"2026-01-01",{"date":36,"type":21},"2031-04-30",{"name":38,"class":39},"Zhengzhou University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100613308","phase-4-zsdt-for-the-treatment-of-rr-mantle-cell-lymphoma-after-btk-inhibitor-failure-a-multi-center-prospective-clinical-trial-100613308","NCT07264894","ZSDT for the Treatment of R\u002FR Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial","ZSDT for the Treatment of Recurrent Refractory Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial","Inclusion Criteria:\n\n1. Ages 18-70, ECOG score 0-2(including ages 18 and 70);\n2. Overall Survival \\> 6 months;\n3. The diagnosis of mantle cell lymphoma was confirmed by histopathology. 4.At least one measurable lesion;\n\n5.Acceptable hematologic parameters, no contraindications to chemotherapy, absolute neutrophil ≥1.0 × 10 \\^ 9 L, platelet ≥75 × 10 \\^ 9 L, hemoglobin ≥80 g\u002FL (except for patients with bone marrow infiltration) 6.Liver function: direct bilirubin ≤1.5 × upper limit , Alanine transaminase or aspartate transaminase ≤2.5 × upper limit , Alkaline phosphatase≤3 × ULN in patients without non-bone involvement 7.Renal function: serum creatinine ≤1.5 ×ULN 5; 8.Women of Childbearing Potential (WOBCP) or men and their WOBCP partners should agree to take effective contraceptive measures from the signing of ICF and WOBCP must undergo a serum pregnancy test within seven days before the first medication and the results are negative; 9.Recurrent refractory patients after BTK inhibitor treatment; 10.The subjects voluntarily participate the study.\n\nExclusion Criteria:\n\n1. Refusing to take blood samples;\n2. Previous allergies to any of the medications in the regimen;\n3. Pregnant and lactating women;\n4. The researchers believe that major diseases can cause interference in the trial.;\n5. Combined with other tumors.;\n6. There are drug-related contraindications to treatment in the protocol;\n7. People with severe mental illness;\n8. Participating in other clinical trials;\n9. Other serious diseases that may limit the subject's participation in this trial, such as: uncontrolled diabetes mellitus; Severe cardiac insufficiency (NYHA classification II or above); Acute coronary syndrome within the past 6 months; Coronary revascularization such as stenting, coronary artery bypass surgery, and other heart and large vessel related surgeries in the past 6 months; Severe arrhythmias include frequent premature ventricular episodes, ventricular tachycardia, rapid atrial fibrillation\u002Fatrial flutter, and severe bradycardia. Uncontrolled hypertension: systolic blood pressure \\> 150 mmHg, diastolic blood pressure \\> 100 mmHg. Gastric ulcer (gastric ulcer judged by the investigator to be at risk of perforation); Active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, autoimmune thrombocytopenia, etc.); Severe respiratory diseases (such as obstructive pulmonary disease and history of bronchospasm), etc.;\n10. In the opinion of the investigators, it is not suitable for enrollment;\n11. Hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is not within the normal reference value; Those who are positive for hepatitis C virus (HCV) antibody and positive for hepatitis C virus (HCV) RNA in peripheral blood; Those who are positive for human immunodeficiency virus (HIV) antibodies; Those who test positive for syphilis.","70 Years",{"count":49,"type":21},30,[51],"PHASE4","For relapsed\u002Frefractory mantle cell lymphoma patients that previously treated with BTK inhibitors: The first part involves 6 cycles of combined therapy with zuberitamab, selinexor, dexamethasone, and thalidomide. This targeted combination regimen can enhance efficacy while reducing toxic side effects. The second part utilizes Zuberitamab plus selinexor for maintenance consolidation therapy, thereby reducing relapse and prolonging survival.",[54],"Mantle Cell Lymphoma (MCL)","2025-11-24",{"date":57,"type":32},"2025-12-04",{"date":59,"type":21},"2025-12-31",{"date":61,"type":21},"2028-12-31",{"name":38,"class":39},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100608200","relmacabtagene-autoleucel-combined-with-autologous-hematopoietic-stem-cell-transplantation-orelabrutinib-and-sintilimab-for-primary-central-nervous-system-lymphoma-100608200","NCT07198464","Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma","A Prospective, Multicenter Clinical Study of Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma","Inclusion Criteria:\n\n1.18-60 years 2.ECOG performance status 0-2 3.No prior treatment with CAR-T cell therapy or autologous stem cell transplantation (ASCT) 4.Expected survival ≥ 3 months 5.No history of malignancy (except for in situ carcinoma or other indolent malignancies), or inactive malignancy with treatment completed \\>1 year ago 6.Histopathologically confirmed PCNSL (lymphoma confined to the brain without systemic involvement, with histopathological type being diffuse large B-cell lymphoma, or systemic lymphoma with central nervous system involvement and histopathological type being diffuse large B-cell lymphoma) 7.Refractory disease is defined as failure to achieve complete remission after first-line therapy (excluding intolerance to first-line therapy), including: Progressive disease (PD) as best response to first-line therapy, or Stable disease (SD) as best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP), or Residual disease after at least 6 cycles of first-line therapy, or relapse within 12 months after completing first-line therapy 8.Relapsed disease is defined as recurrence after achieving complete remission following first-line therapy, occurring within 12 months after treatment completion 9.Positive CD19 expression by immunohistochemistry 10.No contraindications for CAR-T cell therapy or ASCT 11.No concurrent use of other anti-tumor therapies during this treatment; bisphosphonates for bone metastases and symptomatic supportive treatments are allowed 12.Able to understand the study and provide signed Informed Consent Form\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Any uncontrolled medical condition (including active infection, uncontrolled diabetes, severe cardiac, hepatic or renal insufficiency, interstitial pneumonia, etc.)\n3. Use of systemic corticosteroids within 7 days before CD19 CAR-T cell infusion (except ≤ 5 mg\u002Fday dexamethasone or equivalent doses of other corticosteroids)\n4. Prior exposure to ≥ 2 of the following agents with documented resistance: orelabrutinib, fotemustine, carmustine, thiotepa, or PD-1\u002FPD-L1 inhibitors\n5. History of autoimmune disease\n6. Presence of cachexia or any other contraindication to chemotherapy\n7. Active, uncontrolled infection\n8. History of poorly controlled psychiatric disorder\n9. Any condition that, in the opinion of the investigator, would preclude safe participation in this trial","60 Years",{"count":49,"type":21},[24],"To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed\u002Frefractory treatment for primary central nervous system diffuse large B-cell lymphoma.",[76],"Primary Central Nervous System Lymphoma (PCNSL)","2025-09-22",{"date":79,"type":32},"2025-09-30",{"date":81,"type":21},"2025-10-07",{"date":83,"type":21},"2029-10-01",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":63},"100601961","phase-1-cd7-car-t-combined-with-autologous-hematopoietic-stem-cell-transplantation-100601961","NCT07117305","CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation","A Clinical Investigation Into the Safety and Efficacy of CD7 Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Combination With Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Relapsed\u002FRefractory T-cell Lymphoma","Inclusion Criteria:\n\n1. With the patient's explicit consent and after signing the informed consent form, the patient is willing and capable of complying with the planned visits, research treatments, laboratory tests and other trial procedures;\n2. Age range: 14 to 65 years old. Both men and women are eligible;\n3. All types of CD7+ T-cell non-Hodgkin's lymphomas (except T-lymphoblastic lymphoma) diagnosed according to the World Health Organization's classification of hematopoietic and lymphoid tissue tumors (2022);\n4. For patients with T-cell lymphoma who are refractory to the first-line chemotherapy regimen or who experience recurrence and resistance after at least the second-line chemotherapy regimen. The following criteria must be met: a. For those patients who had only received first-line treatment previously, if they did not achieve PR after at least 4 cycles of the first-line regimen, or if they did not achieve CR after at least 6 cycles of the first-line regimen; b. Those who experienced recurrence in the early stage (\\\u003C 12 months) after complete remission; or those who experienced recurrence in the late stage (≥ 12 months) and did not achieve remission after one course of standard induction chemotherapy; c. Those who have not achieved remission after treatment with second-line or more chemotherapy regimens;\n5. During the enrollment screening process, the subjects were confirmed to have CD7+ (with CD7 expression ≥ 10%) through pathological histology and\u002For cytology;\n6. Having measurable or evaluable lesions: The target lesion is defined as a lesion within lymph nodes with a long diameter of ≥ 15mm, or an extranodal lesion larger than 10mm (in accordance with the Lugano 2014 criteria); Lesions that have received prior radiotherapy are considered measurable only if there is a clear progression after completing radiotherapy; or PET-positive lesions determined according to the Lugano criteria;\n7. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 to 2, and the estimated survival period is greater than 3 months;\n8. Having appropriate organ functions: a. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be ≤ 3 times the upper limit of normal (ULN). If the abnormality of ALT and AST is judged to be caused by the disease (such as liver infiltration or bile duct obstruction), the thresholds can be relaxed to ≤ 5 times ULN; b. Total serum bilirubin ≤ 2 times ULN, except in cases where Gilbert syndrome is present; patients with Gilbert syndrome whose total bilirubin is ≤ 3 times ULN and direct bilirubin is ≤ 1.5 times ULN can be included; c. Serum creatinine ≤ 1.5 times the upper limit of normal, or creatinine clearance rate ≥ 60 mL\u002Fmin; d. The international normalized ratio (INR) is no more than 1.5 times the upper limit of normal (ULN), and the activated partial thromboplastin time (aPTT) is no more than 1.5 times the ULN; e. Having the lowest level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and a blood oxygen saturation of ≥ 92% in the absence of oxygen supplementation; f. Left ventricular ejection fraction in echocardiography is ≥ 50%; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion or pleural effusion.\n9. Female participants of childbearing potential must have negative blood\u002Furine pregnancy tests within 7 days prior to infusion. All sexually active males and females with reproductive capacity must agree to use highly effective contraception throughout the study and for at least 2 years after administration of the investigational treatment.\n\nExclusion Criteria:\n\n1. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) \\\u003C50%；\n2. Documented history of severe pulmonary impairment；\n3. History of organ transplantation or active graft-versus-host disease (GVHD);\n4. Concurrent other progressive malignancies;\n5. Uncontrolled severe infections;\n6. Severe autoimmune diseases or primary immunodeficiency disorders;\n7. Positive for any of the following: Hepatitis B surface antigen (HBsAg) and\u002For hepatitis B e antigen (HBeAg); Hepatitis B e antibody (HBe-Ab) and\u002For hepatitis B core antibody (HBc-Ab) with HBV-DNA levels above the upper limit of normal (ULN); Hepatitis C virus antibody (HCV-Ab) with detectable HCV RNA; Human immunodeficiency virus antibody (HIV-Ab); Treponema pallidum antibody (TP-Ab); Cytomegalovirus (CMV) DNA above ULN; Epstein-Barr virus (EBV) DNA above ULN；\n8. History of severe hypersensitivity to biological products (including antibiotics);\n9. Pre-existing central nervous system disorders, including but not limited to:\n\n   Uncontrolled epilepsy；Cerebral ischemia\u002Fhemorrhage；Dementia；Cerebellar disorders；\n10. Previous recipients of autologous or allogeneic hematopoietic stem cell transplantation;\n11. Any other severe physical or psychiatric conditions or significant laboratory abnormalities that may: Increase study participation risks；Interfere with study results interpretation; Be deemed by investigators to render the patient unsuitable for study participation;\n12. Presence of lymphoma-related clinical emergencies requiring immediate intervention at screening due to tumor mass obstruction or compression (e.g., intestinal obstruction, vascular compression, etc.).","14 Years","65 Years",{"count":95,"type":21},38,[97,98],"PHASE1","PHASE2","This is a single-arm, open-label, phase I\u002FII clinical trial initiated by investigators to evaluate the safety, tolerability, and preliminary efficacy of CD7-targeted chimeric antigen receptor T cells (CD7 CAR-T) combined with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory CD7-positive T-cell lymphomas. Phase I adopts a standard 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase II expands at the RP2D to further assess efficacy. The study includes lymphodepletion chemotherapy, ASCT, and sequential infusion of CD7 CAR-T cells. The primary objectives include: (1) Evaluate safety\u002Ftolerability of CD7 CAR-T + auto-HSCT in relapsed or refractory CD7-positive T-cell lymphomas. (2) Determine MTD and RP2D. The secondary objectives include: (1) Assess efficacy (overall response rate, complete response, duration of response, progression-free survival and overall survival. (2)Characterize PK\u002FPD profiles. (3)Investigate anti-tumor mechanisms.",[101,102],"CD7+ Lymphoma","T Cell Lymphoma","2025-08-04",{"date":105,"type":32},"2025-08-12",{"date":107,"type":21},"2025-09-01",{"date":109,"type":21},"2027-12-01",{"name":38,"class":39},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":63},"100589567","phase-4-glofitamab-for-consolidation-after-first-line-treatment-of-high-risk-large-b-cell-lymphoma-100589567","NCT06956092","Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","Prospective Clinical Study of Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","Glofitamab","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form.\n2. Age 18-75 years (inclusive, including 18 and 75 years) at screening; no restriction on gender.\n3. Diagnosed with B-cell non-Hodgkin lymphoma according to the 2022 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (5th edition). The following subtypes are included in this trial:\n\n1\\) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), defined as high-risk disease meeting at least one of the following criteria: IPI score of 4-5 at initial diagnosis, TP53 negativity or overexpression (\\>50%) or TP53 mutation identified by gene sequencing, MYC rearrangement, CD5(+), MYC and BCL2 co-expression.\n\n2\\) Follicular lymphoma-transformed large B-cell lymphoma. 3) High-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangement. 4) High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS). 5) Intravascular large B-cell lymphoma. 6) Large tumor mass (≥7.5 cm). 4. Histopathologically and\u002For cytologically confirmed CD20-positive large B-cell lymphoma patients who have achieved CR, Cru, or VGPR after prior first-line treatment with rituximab-containing chemoimmunotherapy.\n\n5\\. Expected survival ≥12 weeks. 6. Target lesion defined as a lymph node-based lesion with a long diameter ≥15 mm or an extranodal lesion \\>10 mm (according to Lugano 2014 criteria); lesions previously treated with radiotherapy must show clear progression post-radiation to be considered measurable.\n\n7\\. Patients with occult or early-stage hepatitis B infection (defined as HBcAb positive and HBsAg negative) are eligible for inclusion if HBV DNA PCR testing is negative. These patients will undergo monthly HBV DNA PCR monitoring. Patients seropositive for HCV antibodies are eligible if HCV RNA PCR testing is negative.\n\n8\\. Adequate bone marrow reserve, defined as: neutrophil count ≥1.0×10\\^9\u002FL; lymphocyte count ≥0.2×10\\^9\u002FL; hemoglobin \\>80 g\u002FL; platelets \\>80×10\\^9\u002FL.\n\n9\\. Non-hematologic toxicities caused by prior treatments (excluding disease-related conditions) must have resolved to ≤Grade 1 prior to enrollment (except alopecia and chemotherapy-induced Grade ≥2 neurotoxicity).\n\n10\\. Appropriate organ function, meeting the following criteria (excluding abnormalities caused by tumor infiltration):\n\n* Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) ≤3 times ULN; total serum bilirubin ≤2 times ULN, unless Gilbert syndrome is present. Patients with Gilbert syndrome can be included if total bilirubin ≤3 times ULN and direct bilirubin ≤1.5 times ULN.\n* Serum creatinine ≤1.5 times ULN or creatinine clearance ≥60 mL\u002Fmin (using Cockcroft-Gault formula: Male CrCl = \\[(140-age) × weight (kg)\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]; Female CrCl = \\[(140-age) × weight (kg) × 0.85\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]).\n* Minimum pulmonary reserve: ≤Grade 1 dyspnea (CTCAE v5.0) and oxygen saturation ≥92% under non-oxygenated conditions.\n* Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; no clinically significant ECG abnormalities; no clinically significant pericardial effusion or pleural effusion.\n* International normalized ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN.\n\n  11\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 12. No central nervous system lymphoma determined by cranial MRI. 13. Women of childbearing potential must have a negative blood\u002Furine pregnancy test within 7 days prior to infusion. All male and female patients capable of reproduction must agree to use effective contraception throughout the study and for at least 2 years after study treatment administration. A patient is deemed capable of reproduction based on their biological ability to conceive and normal sexual activity, as judged by the investigator. Women are deemed incapable of reproduction if they meet at least one of the following criteria: medically-confirmed ovarian failure, hysterectomy, bilateral oophorectomy, or post-menopausal status (defined as cessation of menstruation for at least 12 consecutive months).\n\nExclusion Criteria:\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. History of severe allergy or hypersensitivity reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).\n2. Received autologous hematopoietic stem cell transplantation (ASCT) within 100 days prior to the first dose of Glofitamab; received chimeric antigen receptor T-cell (CAR-T) therapy within 30 days prior to the first dose of Glofitamab.\n3. Previously underwent allogeneic stem cell transplantation or allogeneic CAR-T therapy.\n4. History of solid organ transplantation.\n5. History of acute or chronic active hepatitis B or hepatitis C infection. Patients with a history of hepatitis must demonstrate viral clearance based on standard serological and genetic testing (i.e., hepatitis B surface antibody positive, other markers negative, and HBV DNA PCR negative) to be eligible; other cases require approval from the medical monitor.\n6. Infection with human immunodeficiency virus (HIV).\n7. Known or suspected chronic active Epstein-Barr virus (CAEBV) infection.\n8. Presence of uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding nail bed fungal infections) at screening or occurrence of any serious infection within 4 weeks prior to the first infusion of Glofitamab (as judged by the investigator).\n9. Current or history of central nervous system (CNS) disorders such as seizures, ischemic\u002Fhemorrhagic cerebrovascular events, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychiatric disorders, or autoimmune diseases involving the CNS.\n10. History of autoimmune diseases, including but not limited to: myasthenia gravis, polymyositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome-associated vascular thrombosis, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, glomerulonephritis, or active autoimmune cytopenias (autoimmune hemolytic anemia \\[AIHA\\], idiopathic thrombocytopenic purpura \\[ITP\\]).\n\n    * Patients with long-standing or well-controlled autoimmune diseases may be eligible after discussion and confirmation with the investigator.\n    * Patients with autoimmune thyroid dysfunction receiving stable doses of thyroid replacement hormone may be eligible.\n    * Patients with well-controlled Type 1 diabetes (defined as fasting HbA1c \\\u003C8% at screening and no ketoacidosis) are eligible.\n    * Patients with skin-limited conditions such as eczema, psoriasis, chronic lichen simplex, or vitiligo may be eligible if the following criteria are met:\n\n      * Rash involves \\\u003C10% of body surface area.\n      * Disease is well-controlled at baseline and requires only low-dose topical corticosteroids.\n      * No exacerbations requiring treatment with psoralen plus UVA light, methotrexate, retinoids, biologics, oral calcineurin inhibitors, high-dose or systemic corticosteroids during the past 12 months.\n11. Presence of primary or secondary active CNS lymphoma (patients with symptoms suggestive of CNS involvement must undergo lumbar puncture and MRI to exclude CNS lymphoma).\n12. Prior receipt of other genetically modified T-cell therapy or CAR-T therapy.\n13. Diagnosis of progressive multifocal leukoencephalopathy (PML).\n14. Clinical emergencies requiring urgent intervention due to lymphoma-related obstruction or compression, such as intestinal obstruction or vascular compression, at screening.\n15. Cardiac conditions meeting any of the following: left ventricular ejection fraction (LVEF) ≤45% (by echocardiography); New York Heart Association (NYHA) class III or IV congestive heart failure; severe arrhythmias requiring treatment, including QTc interval ≥450ms for males or ≥470ms for females (QTcB=QT\u002FRR\\^1\u002F2); uncontrolled hypertension (systolic blood pressure ≥140mmHg and\u002For diastolic blood pressure ≥90mmHg), pulmonary hypertension, or unstable angina; history of cardiac angioplasty or stent placement, myocardial infarction, unstable angina, or other clinically significant cardiac conditions within 12 months prior to administration; clinically significant valvular disease; lymphoma involving atrial or ventricular structures; or other cardiac diseases deemed unsuitable by the investigator.\n16. Thromboembolic events (such as deep vein thrombosis or pulmonary embolism) within 6 months prior to screening.\n17. Malignancies other than those indicated for this trial within 5 years prior to screening, except for melanoma, skin carcinoma, or in-situ cancers (e.g., cervical, bladder, breast carcinoma).\n18. Receipt of live attenuated vaccines within 4 weeks prior to the first infusion of Glofitamab or expected need for such vaccines during the study period.\n19. Major surgery within 4 weeks prior to the first infusion of Glofitamab. Protocol-required procedures such as tumor biopsy and bone marrow biopsy are allowed.\n20. Systemic immunosuppressive therapy (including but not limited to azathioprine, methotrexate, thalidomide, or anti-TNF agents) within 2 weeks prior to the first infusion of Glofitamab. Corticosteroid therapy at ≤25 mg\u002Fday prednisone or equivalent is permitted.\n\n    * Inhaled and topical corticosteroids are allowed.\n21. Inability to comply with protocol-mandated hospitalization and activity restrictions.\n22. Pregnant or breastfeeding women, or male or female patients of childbearing potential who refuse to use effective contraception during the study and for 2 years after the cellular infusion.\n23. Participation in another interventional clinical trial, receipt of investigational drugs, or intent to enroll in another trial or receive non-protocol-defined antitumor therapy within 3 months before Glofitamab administration.\n24. Any severe medical condition or laboratory abnormality, as determined by the investigator or medical monitor, that could compromise patient safety, adherence to the protocol, or interpretation of results.\n25. Investigator deems the patient unsuitable for this trial (e.g., poor compliance, substance abuse, etc.).",{"count":120,"type":21},40,[51],"The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are:\n\n* Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?\n* What medical problems do participants have when receiving Glofitamab treatment?\n\nIn this investigator-initiated, single-arm clinical trial, participants will:\n\n* Receive Glofitamab treatment as per the instructions in the package insert.\n* Visit the clinic as instructed for checkups and tests.",[124],"B Cell Lymphoma (BCL)","2025-04-24",{"date":127,"type":32},"2025-05-02",{"date":129,"type":21},"2025-05-30",{"date":131,"type":21},"2028-12",{"name":38,"class":39},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":63},"100562910","phase-4-axicabtagene-ciloleucel-for-consolidation-after-first-line-treatment-of-high-risk-large-b-cell-lymphoma-100562910","NCT06609304","Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","Prospective Clinical Study of Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","axi-cel","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form;\n2. 18-70 years of age (inclusive);\n3. Previously untreated CD19-positive large B-cell lymphoma;\n4. Anticipated survival ≥12 weeks;\n5. Adequate bone marrow reserve prior to apheresis\n6. Appropriate organ function:\n7. Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma;\n\n9\\. Negative blood\u002Furine pregnancy test in women of childbearing age.\n\nExclusion Criteria:\n\n1. History of allergy to any of the components of the cell product;\n2. History of stem cell transplantation;\n3. History of organ transplantation;\n4. Presence of active infections;\n5. Current or history of central nervous system disorders;\n6. Previous treatment with other modified T-cell therapy;\n7. Previous treatment with anti-CD19\u002FCD3 or other anti-CD19 therapies;\n8. Malignancies other than those indicated for this trial;\n9. History of any prior systemic immune checkpoint therapy;\n10. History of short-acting cell growth factors or haematopoietic agonists\u002Fstimulants ;\n11. History of a live vaccine within 3 months prior to screening;.",{"count":142,"type":21},20,[51],"The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are:\n\n* Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?\n* What medical problems do participants have when receiving axi-cel treatment?\n\nIn this investigator-initiated, single-arm clinical trial, participants will:\n\n* Receive atezolizumab treatment at 2.0×10\\^6 cells\u002FKg as a one-time therapy.\n* Visit the clinic as instructed for checkups and tests.",[146],"Lymphoma, B-Cell","RECRUITING","2024-10-09",{"date":150,"type":32},"2024-10-15",{"date":152,"type":21},"2024-09-30",{"date":154,"type":21},"2027-08-31",{"name":38,"class":39},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":164,"targetDuration":166,"studyType":167,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":63},"100478164","a-clinical-study-of-hanlikang-and-btk-inhibitors-in-the-treatment-of-newly-diagnosed-mantle-cell-lymphoma-100478164","NCT05506410","A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma","A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma","Inclusion Criteria:\n\n1. Age 18-70, ECOG score 0-2;\n2. Estimated survival time \\>6 months;\n3. Mantle cell lymphoma was confirmed by pathology.\n4. Acceptable hematological indexes without chemotherapy contraindications; Neutrophil absolute value ≥1.0×10\\^9 \u002FL, PLT≥75×10\\^9 \u002FL, hemoglobin ≥80g\u002FL (except patients with lymphoma bone marrow infiltration);\n5. At least one measurable lesion. For intrnodal lesions, they were defined as long diameter ≥1.5cm and short diameter ≥1.0cm; For r extranodal lesions, the length should be ≥1.0cm;\n\n7\\. Liver function: TBIL≤1.5×ULN; ALT or AST ≤2.5 x ULN; Alkaline phosphatase ≤3×ULN in patients with non-bone invasion;\n\n8\\. Kidney function: serum creatinine ≤1.5×ULN;\n\n9\\. Excluding other major diseases, the heart function is normal;\n\n10 Women and men of childbearing age and their spouses are willing to use adequate contraception throughout the study period, and women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose;\n\n11 Subjects voluntarily participated in the clinical trial, signed the informed consent form, and cooperated with the follow-up;\n\n12\\. There is no other relevant treatment including traditional Chinese medicine (anti-tumor), immunotherapy, biologic therapy (except anti-bone metastasis and other symptoms);\n\nExclusion Criteria:\n\n1. Patients with definite neuropathy or psychosis, including dementia or seizures, a history of psychotropic substance abuse and inability to abstinence, or other substantial lesions that may increase CNS toxicity;\n2. Participating in other clinical trials or participating in other clinical investigators 4 weeks before enrollment (except those not receiving treatment);\n3. Systemic autoimmune disease or immune deficiency;\n4. Refusing to collect blood samples;\n5. Allergic to any drug in the protocol;\n6. Pregnant and lactating women;\n7. Major diseases that can cause test interference and uncontrolled active infected persons;\n8. Primary or secondary central tumor;\n9. Contraindications to chemotherapy;\n10. Not considered suitable for inclusion.\n11. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (other than nail bed skin fungal infections) or any major systemic infection event requiring intravenous antibiotic treatment or hospitalization (other than neoplastic fever) within 4 weeks prior to enrollment;\n\n13\\. Application of other antitumor therapies (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy);\n\n14\\. Other serious medical conditions that may limit the subject's participation in the study, such as uncontrolled diabetes; Severe cardiac insufficiency (NYHA grade II or above); Acute coronary syndrome in the last 6 months; Coronary revascularization such as stenting, cabG, and other cardiac and macrovascular procedures within the last 6 months; Severe arrhythmias include frequent ventricular premature, ventricular tachycardia, rapid atrial fibrillation\u002Fflutter, and severe bradycardia. Uncontrolled hypertension: systolic blood pressure \\>150mmHg, diastolic blood pressure \\>100mmHg. Gastric ulcers (those identified by the investigators as being at risk for perforation); Active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.); Severe respiratory diseases (e.g. obstructive pulmonary disease and history of bronchospasm), etc.;\n\n15\\. Hemophagocytic cell syndrome;\n\n16\\. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) was positive, and the peripheral blood hepatitis B virus (HBV) DNA titer was not within the normal reference range; Hepatitis C virus (HCV) antibody positive and HCV RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA test positive; Who tested positive for syphilis.","90 Years",{"count":165,"type":21},100,"2 Years","OBSERVATIONAL","An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma",[170],"Newly Diagnosed Mantle Cell Lymphoma","2022-08-17",{"date":173,"type":32},"2022-08-18",{"date":175,"type":32},"2022-08-12",{"date":177,"type":21},"2026-12-30",{"name":38,"class":39},""]